List of publications 289 A List of publications Hummelink K, van der Noort V, Muller M, Schouten RD, van den Heuvel MM, Thommen DS, Smit EF, Meijer GA, Monkhorst K. Head-to-head comparison of composite and individual biomarkers to predict clinical benefit to PD-1 blockade in non-small cell lung cancer. PloS One. 2024 Jul 31;19(7):e0293707. Doi: 10.1371/journal. pone.0293707. eCollection 2024. Van de Haar J*, Mankor JM*, Hummelink K, Monkhorst K, Smit EF, Wessels LFA, Cuppen E#, Aerts JGJV#, Voest EE#. Combining genomic biomarkers to guide immunotherapy in non-small cell lung cancer. Clin Cancer Res. 2024 Apr 1;30(7):13071318. Doi: 10.1158/1078-0432.CCR-23-4027. *Co-first author. #These authors jointly supervised this work. Hummelink K, Tissier R, Bosch LJW, Krijgsman O, van den Heuvel MM, Theelen WSME, Damotte D, Goldwasser F, Leroy K, Smit EF, Meijer GA#, Thommen DS#, Monkhorst K#. A dysfunctional T cell gene signature for predicting non-response to PD-1 blockade in non-small cell lung cancer that is suitable for routine clinical diagnostics. Clin Cancer Res. 2024 Feb 16;30(4):814-823. Doi: 10.1158/1078-0432.CCR-23-1061. #These authors jointly supervised this work. Murray JC*, Sivapalan L*, Hummelink K*, Balan A, White JR, Niknafs N, Rhymee L, Pereira G, Rao N, Weksler B, Bahary N, Phallen J, Leal A, Bartlett DL, Marrone KA, Naidoo J, Goel A, Levy B, Rosner S, Hann CL, Scott SC, Feliciano J, Lam VK, Ettinger DS, Kay Li Q, Illei PB, Monkhorst K, Scharpf RB, Brahmer JR, Velculescu VE, Zaidi AH#, Forde PM#, Anagnostou V#. Elucidating the heterogeneity of immunotherapy response and immune-related toxicities by longitudinal ctDNA and immune cell compartment tracking in lung cancer. Clin Cancer Res. 2024 Jan 17;30(2):389-403. Doi: 10.1158/1078-0432.CCR-23-1469. *Co-first author. #These authors jointly supervised this work. Muller M*, Best MG*, van der Noort V, Hiltermann TJN, Niemeijer AN, Post E, Sol N, in ‘t Veld SGJG, Nogarede T, Visser L, Schouten RD, van den Broek D, Hummelink K, Monkhorst K, de Langen AJ, Schuuring E, Smit EF, Groen HJM, Wurdinger T, van den Heuvel MM. Blood platelet RNA profiles do not enable for nivolumab response prediction at baseline in patients with non-small cell lung cancer. Tumour Biol. 2024;46(s1):S327-S340. Doi: 10.3233/TUB-220037. *Co-first author.
RkJQdWJsaXNoZXIy MTk4NDMw